NEWS Oncoscience signs contract with YM Biosciences Inc. ByOncoscience 15. November 200317. July 2025 Read the press release Download: >> press_release_YM_Biosciences (.pdf 28kB) Ähnliche Beiträge
NEWS Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer ByOncoscience 28. May 202217. July 2025
NEWS The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively ByOncoscience 26. October 200717. July 2025
NEWS Oncoscience AG attends the Nimotuzumab Global Scientific Meeting, 7th-10th April 2016 in Varadero/ Cuba ByOncoscience 7. April 201617. July 2025
NEWS YM Biosciences and Oncoscience AG achieve clinical milestone ByOncoscience 10. January 200517. July 2025
NEWS Oncoscience AG announces completion of patient enrollment in phase III trial of NIMOTUZUMAB, in first line treatment of children with inoperable brain cancer ByOncoscience 12. September 200717. July 2025
